Published in Eur J Med Chem on January 20, 2010
Access to pyrrolo-pyridines by gold-catalyzed hydroarylation of pyrroles tethered to terminal alkynes. Beilstein J Org Chem (2011) 0.75
An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol (2005) 3.36
Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology (2009) 3.16
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology (2006) 1.99
Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties. Bioorg Med Chem Lett (2003) 1.97
The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol (2005) 1.91
Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antiviral Res (2009) 1.87
Influence of 2-substituent on the activity of imidazo[1,2-a] pyridine derivatives against human cytomegalovirus. Bioorg Med Chem (2002) 1.77
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One (2010) 1.59
Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells. PLoS One (2011) 1.52
Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature (2005) 1.51
Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics. J Antimicrob Chemother (2011) 1.51
Selective inhibitors of picornavirus replication. Med Res Rev (2008) 1.50
A case for developing antiviral drugs against polio. Antiviral Res (2008) 1.50
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother (2008) 1.46
In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors. J Hepatol (2011) 1.45
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun (2004) 1.42
Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol (2011) 1.37
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents. Antiviral Res (2007) 1.33
Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res (2008) 1.31
Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication. Cell Res (2012) 1.27
Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother (2011) 1.23
New 3- and 4-hydroxyfuranones as anti-oxidants and anti-inflammatory agents. Bioorg Med Chem (2005) 1.19
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother (2008) 1.18
Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J Virol (2010) 1.17
Substituted 5-benzyl-2-phenyl-5H-imidazo[4,5-c]pyridines: a new class of pestivirus inhibitors. Bioorg Med Chem Lett (2006) 1.13
Antiviral strategies to control calicivirus infections. Antiviral Res (2010) 1.11
Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections. Rev Med Virol (2004) 1.11
Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus. J Hepatol (2012) 1.11
A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase IIIβ. Antimicrob Agents Chemother (2013) 1.11
A multifaceted study of Pseudomonas aeruginosa shutdown by virulent podovirus LUZ19. MBio (2013) 1.11
Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention. Trends Pharmacol Sci (2007) 1.10
Interferons, interferon inducers, and interferon-ribavirin in treatment of flavivirus-induced encephalitis in mice. Antimicrob Agents Chemother (2003) 1.09
Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay. Antiviral Res (2004) 1.09
The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology (2012) 1.07
The viral polymerase inhibitor 2'-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model. J Virol (2013) 1.05
Selective inhibition of hepatitis B virus replication by RNA interference. Biochem Biophys Res Commun (2003) 1.05
Potential use of antiviral agents in polio eradication. Emerg Infect Dis (2008) 1.05
Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication. Antiviral Res (2013) 1.03
3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J Virol (2013) 1.03
Complete genome sequence, taxonomic assignment, and comparative analysis of the untranslated regions of the Modoc virus, a flavivirus with no known vector. Virology (2002) 1.02
The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C. J Virol (2008) 1.02
Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol (2011) 1.02
A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro. Antimicrob Agents Chemother (2010) 1.02
Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother (2009) 1.01
Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine. Antimicrob Agents Chemother (2006) 1.00
Inhibition of subgenomic hepatitis C virus RNA replication by acridone derivatives: identification of an NS3 helicase inhibitor. J Med Chem (2009) 1.00
The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol Pharmacol (2006) 1.00
Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev Med Virol (2008) 1.00
Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother (2012) 1.00
Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation (2006) 0.99
Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice. PLoS One (2011) 0.99
Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol (2013) 0.97
Mass spectrometry and scanning electron microscopy study of silicone tunneled dialysis catheter integrity after an exposure of 15 days to 60% ethanol solution. Rapid Commun Mass Spectrom (2007) 0.97
Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection. Virology (2009) 0.97
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine. J Med Chem (2006) 0.97
Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Antiviral Res (2011) 0.96
The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. Antiviral Res (2011) 0.96
Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and mice. J Pharmacol Exp Ther (2009) 0.96
Towards the design of combination therapy for the treatment of enterovirus infections. Antiviral Res (2011) 0.95
Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication. Antimicrob Agents Chemother (2011) 0.95
Selective serotonin reuptake inhibitor fluoxetine inhibits replication of human enteroviruses B and D by targeting viral protein 2C. Antimicrob Agents Chemother (2013) 0.95
Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob Agents Chemother (2007) 0.94
Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. Antiviral Res (2011) 0.93
Massive cell vacuolization induced by organic amines such as procainamide. J Pharmacol Exp Ther (2004) 0.93
Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses (2010) 0.93
Hepatitis C virus-specific directly acting antiviral drugs. Curr Top Microbiol Immunol (2013) 0.93
Differential effects of the putative GBF1 inhibitors Golgicide A and AG1478 on enterovirus replication. J Virol (2010) 0.93
Hepatitis B virus replication causes oxidative stress in HepAD38 liver cells. Mol Cell Biochem (2006) 0.92
Exchanging the yellow fever virus envelope proteins with Modoc virus prM and E proteins results in a chimeric virus that is neuroinvasive in SCID mice. J Virol (2004) 0.92
The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob Agents Chemother (2004) 0.92
Anti-enterovirus activity and structure-activity relationship of a series of 2,6-dihalophenyl-substituted 1H,3H-thiazolo[3,4-a]benzimidazoles. Biochem Biophys Res Commun (2006) 0.92
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. Antimicrob Agents Chemother (2008) 0.92
2'-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Res (2006) 0.91
Discovery of a novel HCV helicase inhibitor by a de novo drug design approach. Bioorg Med Chem Lett (2009) 0.91
Novel 1,2,4-triazole and imidazole derivatives of L-ascorbic and imino-ascorbic acid: synthesis, anti-HCV and antitumor activity evaluations. Bioorg Med Chem (2012) 0.90
Heterocyclic rimantadine analogues with antiviral activity. Bioorg Med Chem (2006) 0.90
The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication. Biochem Pharmacol (2012) 0.89
Heterocyclic rimantadine analogues with antiviral activity. Bioorg Med Chem (2003) 0.88
Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrob Agents Chemother (2013) 0.88
Recent progress in the pharmacology of imidazo[1,2-a]pyridines. Mini Rev Med Chem (2007) 0.88
Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo. Antimicrob Agents Chemother (2013) 0.88
Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues. Bioorg Med Chem Lett (2008) 0.87
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma. J Med Chem (2008) 0.87
Identification of allosteric inhibitors blocking the hepatitis C virus polymerase NS5B in the RNA synthesis initiation step. Antiviral Res (2009) 0.87
Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. Antivir Ther (2008) 0.87
Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family. Antimicrob Agents Chemother (2011) 0.87